CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?

Janssen's Invokana reduced cardiovascular events in CANVAS on par with the MACE reduction in Lilly's and Boehringer's EMPA-REG trial for competing SGLT2 inhibitor Jardiance, but the CV benefit comes with a doubling of amputation risk versus placebo.

Diabetes

Johnson & Johnson subsidiary Janssen Pharmaceutical Cos. reported a 14% reduction in the risk of major cardiovascular events for Invokana (canagliflozin) in the CANVAS outcomes trials, which was the same MACE reduction observed in the EMPA-REG trial for competing SGLT2 inhibitor Jardiance (empagliflozin), but it may be too early to declare the drugs' cardiovascular benefits – and Invokana's amputation risk – a class effect.

[Sidebar#SC098432]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category